Forecast
There is no analyst data available for this company.
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
In the last quarter, ONCOTHERAPY SCIENCE INC. had revenue of €924.02k and net profit of -€1.6m
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 924.02k | 30.35% |
| Gross profit | -97.11k | 151.75% |
| Net profit | -1.6m | 15.56% |
| EBITDA | -1.59m | 14.98% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €32.85m |
Number of shares | 408.24m |
52-week high/low | €0.20 - €0.0805 |
| Dividends | No |
Beta | 0.33 |
P/E ratio | -6.09 |
PEG ratio | -0.27 |
P/B ratio | 2.77 |
P/S ratio | 8.02 |
Company profile
OncoTherapy Science, Inc. researches and develops anti-cancer medicines and therapies in Japan. Its clinical development product pipeline includes small-molecule drugs, such as OTS167, a maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a T-LAK cell-originated protein kinase inhibitor for the treatment of various cancer diseases. The company's clinical development product pipeline also comprise cancer- specific peptide vaccines, including S-588410, which is in Phase III clinical trials for the treatment esophageal cancer, as well as in Phase II clinical trials for the treatment of bladder cancer; S-488210 that is in Phase I/II clinical trials for the treatment of head and neck cancer; and S-588210, which is in Phase I clinical trials for the treatment of solid tumor. In addition, it is developing antibody drugs consisting of OTSA101, which is in Phase I clinical trials for synovial sarcoma; and KHK6640, an anti-amyloid beta peptide antibody that is Phase I clinical trials for Alzheimer's disease. Further, the company provides contract analysis services. OncoTherapy Science, Inc. was founded in 2001 and is headquartered in Kawasaki, Japan.
| Name | ONCOTHERAPY SCIENCE INC. |
| CEO | Junichi Shimada |
| Headquarters | Kawasaki,
kn Japan |
| Website | |
| IPO | 29/09/2005 |
| Employees | 46 |
Deep Dive
Ticker symbols
| Exchange | Symbol |
|---|---|
Japan Exchange Group | 4564.T |
Frankfurt | 30O.F |
München | 30O.MU |
Düsseldorf | 30O.DU |